BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Job Trends

  Hiring Outlook: Biopharma Job Market Yet To Surge, but Layoffs Decline

  Although the job market did not pick up in April, layoffs were down year over year and month over month, according to BioSpace tallies. Meanwhile, Amgen, Novartis, Regeneron and Roche announced U.S. manufacturing investments that are sparking job creation.

  May 7, 2025

   · 

  3 min read

   · 

  Angela Gabriel
• 

  Manufacturing

  Amid Trump’s Trade War, Some Drugmakers Stockpile Products in U.S.

  Imports of pharmaceutical products surged in March, most of which came from Ireland, historically one of the biggest exporters of medicines to the U.S.

  May 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  Recent Federal Actions Put US, Massachusetts Biotech Leadership at Risk: MassBio

  MassBio’s new report outlines several concerns, including NIH cuts undermining the research engine, FDA reductions delaying innovation and trade barriers disrupting supply chains.

  May 7, 2025

   · 

  3 min read

   · 

  Angela Gabriel
• 

  Gene therapy

  CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025

  CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy Casgevy. While Vertex handles the market, CRISPR has been focused on its clinical program.

  May 7, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Cancer

  C4 Therapeutics Shelves BRAF Blocker, Goes All-In on Multiple Myeloma Drug

  The Massachusetts biotech will focus its efforts and resources into cemsidomide, an oral drug candidate being trialed for multiple myeloma and non-Hodgkin lymphoma.

  May 7, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Deals

  M&A, IPOs Snarled by Policy Reality in Q1 as Pharmas Opt for Licensing Deals

  M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing transactions, however, grew as pharmas looked for less-risky deals.

  May 7, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Novo Vows Smoother Market Waters for Wegovy—but Analysts Are Skeptical

  The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the market position of Wegovy. But Eli Lilly’s Zepbound is quickly gaining ground, with sales just $300 million behind Wegovy in Q1.

  May 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Summit’s Campaign To Conquer Keytruda Nears First Global Phase III Data

  Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other branded drugmakers are also seeking to improve on the blockbuster checkpoint inhibitor.

  May 7, 2025

   · 

  5 min read

   · 

  Nick Paul Taylor
• 

  Podcast

  Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review

  A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will require placebo-controlled trials for all vaccine approvals; tariff threats hit BioNTech; Novo Nordisk’s FDA application for an oral version of Wegovy is accepted; and more.

  May 7, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Vaccines

  Is the New HHS Vaccine Requirement Anti-Vaccine Activism Disguised as Policy?

  Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for vaccines and sought greater clarity: “I don’t know what they’re talking about.”

  May 7, 2025

   · 

  6 min read

   · 

  Heather McKenzie